Search | Clinical Trials Finder

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Primaquine, Sulfamethoxazole-Trimethoprim, Dapsone, Clindamycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 32
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 23 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Dapsone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 12 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 29 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate, Pyrimethamine, Sulfamethoxazole/Trimethoprim, Sulfadoxine/Pyrimethamine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 6 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 6 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 11
States / cities: Los Angeles, California • Oakland, California • Washington D.C., District of Columbia + 4 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Trimethoprim, Sulfamethoxazole, Dapsone, Leucovorin calcium; Drug
Lead sponsor: U.S. Bioscience; Industry
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 2 more

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions: Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo; Drug
Lead sponsor: Mundipharma Research Limited; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate, Dapsone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 14
States / cities: San Francisco, California • Denver, Colorado • Wilmington, Delaware + 10 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 23
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 15 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 53
States / cities: Birmingham, Alabama • Harbor City, California • Los Angeles, California + 30 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Methylprednisolone, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1989
U.S. locations: 1
States / cities: West Columbia, South Carolina

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone, Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 27
States / cities: Birmingham, Alabama • Harbor City, California • Los Angeles, California + 15 more

Conditions: Pneumocystis Infection, Infection, Pneumonia, Pneumocystis, Lung Disease, Fungal, Mycoses
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 99 Years
Enrollment: 1,015 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Covid19, Aspergillosis, Fungal Infection
Interventions: Observation to monitor patients for these infections; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Leucovorin calcium; Drug
Lead sponsor: U.S. Bioscience; Industry
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: West Conshohocken, Pennsylvania

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Primaquine, Clindamycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 3 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Leucovorin calcium; Drug
Lead sponsor: U.S. Bioscience; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: West Conshohocken, Pennsylvania

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 40
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Conditions: HIV Infections, Pneumocystis Pneumonia, Emphysema, Chronic Obstructive Pulmonary Disease, Asthma
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone, Pentamidine isethionate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Maitland, Florida • Tampa, Florida • New York, New York + 2 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 5
States / cities: San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 2 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Methylprednisolone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 28 Days to 2 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: La Jolla, California • Chicago, Illinois • St Louis, Missouri + 2 more

Conditions: HIV Infections
Interventions: Fat Emulsion 2%, Fat Emulsion 20%; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: East Orange, New Jersey

Search by objective public record fields.

A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)

A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Children Who Cannot Take Trimethoprim-Sulfamethoxazole

Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia

A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides

Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts

Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients

A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients

New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia

COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)

A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia

A Study of Neutrexin Plus Leucovorin in the Treatment of Pneumocystis Carinii Pneumonia (PCP)

The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS

A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia

Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis

Pneumocystis in Pathogenesis of HIV-associated Emphysema

A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX

Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children

The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS

A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)